|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI
|
|
2
|
Haake SM and Rathmell WK: Renal cancer
subtypes: Should we be lumping or splitting for therapeutic
decision making? Cancer. 123:200–229. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheaib JG, Patel HD, Johnson MH, Gorin MA,
Haut ER, Canner JK, Allaf ME and Pierorazio PM: Stage-specific
conditional survival in renal cell carcinoma after nephrectomy.
Urol Oncol. 38:6.e1–6.e7. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pichler M, Hutterer GC, Stoeckigt C,
Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A,
Mannweiler S, Pummer K, et al: Validation of the pre-treatment
neutrophil-lymphocyte ratio as a prognostic factor in RCC. Br J
Cancer. 108:901–907. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jagdev SP, Gregory W, Vasudev NS, Harnden
P, Sim S, Thompson D, Cartledge J, Selby PJ and Banks RE: Improving
the accuracy of pre-operative survival prediction in RCC with CRP.
Br J Cancer. 103:1649–1656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirata H, Fujii N, Oka S, Nakamura K,
Shimizu K, Kobayashi K, Hiroyoshi T, Isoyama N and Shiraishi K:
CALLY index as a novel biomarker for progression in RCC. Cancer
Diagn Progn. 4:748–753. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iida H, Tani M, Komeda K, Nomi T,
Matsushima H, Tanaka S, Ueno M, Nakai T, Maehira H, Mori H, et al:
Superiority of CRP-albumin-lymphocyte index (CALLY index) as a
non-invasive prognostic biomarker after hepatectomy for
hepatocellular carcinoma. HPB (Oxford). 24:101–115. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng J, Wang L, Yang X and Chen Q:
Clinical significance of preoperative CALLY index in esophageal
SCC. Sci Rep. 14:7132024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sakurai K, Kubo N, Hasegawa T, Nishimura
J, Iseki Y, Nishii T, Inoue T, Yashiro M, Nishiguchi Y and Maeda K:
CALLY index in gastric cancer prognosis. World J Surg.
48:2749–2759. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu MT, He SY, Chen SL, Li LF, He ZQ, Zhu
YY, He X and Chen H: Clinical and prognostic implications of
pretreatment albumin to C-reactive protein ratio in patients with
hepatocellular carcinoma. BMC Cancer. 19:5382019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ishizuka M, Ishizuka M, Nagata H, Takagi
K, Horie T and Kubota K: Inflammation-based prognostic score is a
novel predictor of postoperative outcome in patients with
colorectal cancer. Ann Surg. 246:1047–1051. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou L, Cai X, Liu Q, Jian ZY, Li H and
Wang KJ: Prognostic role of C-reactive protein in urological
cancers: A meta-analysis. Sci Rep. 5:127332015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Patel SH, Derweesh IH, Saito K, Patil D,
Meagher MF, Bindayi A, Eldefrawy A, Patel DN, Nasseri R, Yasuda Y,
et al: Preoperative elevation of C-reactive protein is a predictor
for adverse oncologic survival outcomes for renal cell carcinoma:
Analysis from the International Marker Consortium Renal Cancer
(INMARC). Clin Genitourin Cancer. 19:e206–e215. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McMillan DC: The systemic
inflammation-based Glasgow Prognostic Score: A decade of experience
in patients with cancer. Cancer Treat Rev. 39:534–540. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li W and Wang J: The current state of
inflammation-related research in prostate cancer: a bibliometric
analysis and systematic review. Front Oncol. 14:14328572024.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iivanainen S, Ahvonen J, Knuuttila A,
Tiainen S and Koivunen JP: Elevated CRP levels indicate poor
progression-free and overall survival on cancer patients treated
with PD-1 inhibitors. ESMO Open. 4:e0005312019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johnson TV, Abbasi A, Owen-Smith A, Young
AN, Kucuk O, Harris WB, Osunkoya AO, Ogan K, Pattaras J, et al:
Postoperative better than preoperative C-reactive protein at
predicting outcome after potentially curative nephrectomy for renal
cell carcinoma. Urology. 76:766–e1. 2010. View Article : Google Scholar
|
|
19
|
Onodera R, Chiba S, Nihei S, Fujimura I,
Akiyama M, Utsumi Y, Nagashima H, Kudo K and Maemondo M: High level
of C-reactive protein as a predictive factor for immune-related
adverse events of immune checkpoint inhibitors in non-small cell
lung cancer: A retrospective study. J Thorac Dis. 15:4237–4247.
2023. View Article : Google Scholar : PubMed/NCBI
|
